Navigation Links
Generics Analysis: Key Patent Case Reviews
Date:9/20/2012

NEW YORK, Sept. 20, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Generics Analysis: Key Patent Case Reviews

http://www.reportlinker.com/p0968573/Generics-Analysis-Key-Patent-Case-Reviews.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Providing clarity regarding generic launch timing that will shape the market around Eli Lilly's antidepressant Cymbalta and Celgene's oncology drug Revlimid.Detailed analysis of the likely date of generic entry for Cymbalta and RevlimidAnalysis of both products' position in their companies total prescription pharma portfolioCelgene is heavily dependent upon the performance of Revlimid (lenalidomide). The product generated $3.2bn in 2011, or 68.3% of the company's total sales.The only generic version submitted so far in the US is from Natco and partner Watson. A 30-month stay runs until December 2013 and the companies have been sued for infringement of 14 patents covering Revlimid, which expire across 2016–27.In 2012 and 2013, Cymbalta is forecast to account for 17.5% of Eli Lilly's total five major EU market sales. As such, generic launch timing will have a significant impact.Gain clarity on when Cymbalta and Revlimid are likely to face generic competitionAssess the threat to Eli Lilly and Celgene of these products' genericization

 

GENERIC ENTRY TIMING REVIEWS•Key findings

•Cymbalta (duloxetine; Eli Lilly) - EU launch of generic Cymbalta from August 2014

•Revlimid (lenalidomide; Celgene) - Natco sued for infringement of 14 patents

 

APPENDIX•References

•Exchange rates

 

TABLES

•Table: Cymbalta: patent protection and exclusivity in Europe

•Table: Revlimid: patent protection and exclusivity in the US

•Table: Exchange rates, 2012

 

FIGURES

•Figure: Cymbalta/Xeristar and Eli Lilly total five major EU market sales, 2002–17

•Figure: Revlimid and total Celgene sales, 2002–17

•Figure: US patent and exclusivity timeline relating to Revlimid

•Figure: Chemical structure of lenalidomide

 

Companies Mentioned

Devoteam SA, Hutchison 3G UK Limited

 

To order this report:

Drug_and_Medication Industry: Generics Analysis: Key Patent Case Reviews

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
2. Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth
3. Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
4. Branded Generics in South East Asia: Current and Future Opportunities
5. Essential Medical Dismisses Patent Case against Masimo and Cercacor
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
8. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
9. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
10. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
11. Broad Patent Protection Granted for iBio Immunomodulator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 ... Review, H1 2016" is a report that provides ... helps strengthen R&D pipelines by identifying new targets ... Company Profiles discussed in this H1 ... Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., ...
(Date:4/27/2016)... le 27 Avril 2016 ... progressé de +5% sur le trimestre, soutenu par ... consommables  Croissance de +16% des ventes ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : ... laser, annonce aujourd,hui son chiffre d,affaires pour le ...
(Date:4/27/2016)... York , April 27, 2016 ... report titled, "Skincare Devices Market - Global Industry Analysis, ... According to the report, the global skincare devices market ... is anticipated to expand at a CAGR of 10.1% ... in 2023. Browse the full Skincare Devices Market ...
Breaking Medicine Technology:
(Date:5/2/2016)... MA (PRWEB) , ... May 02, 2016 , ... Pregnancy ... tips when trying to conceive. , “If you are ready to have ... Mache Seibel. “My book, HealthChequesTM: Journal Babies is your Personal Conception & Pregnancy ...
(Date:5/2/2016)... ... May 02, 2016 , ... TeleMedCo™, a new company ... automate and improve the rapid diagnosis, triage and admission of patients leveraging IBM ... and mobile experience for the first time at GENBAND’s Perspectives16 conference. , ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... Research & Analytics EVP and GM Jim Callandrillo and Duane Reed, VP ... 55th Annual Pharmaceutical Business Intelligence and Research Group (PBIRG) General Meeting ...
(Date:5/2/2016)... ... May 02, 2016 , ... Atlantic Information Services, Inc. (AIS) is pleased ... Model Could Transform the Pharma Landscape .” CMS recently proposed a test of alternate ... provider-administered drugs while preserving care provided to beneficiaries. The webinar will review the details ...
(Date:5/2/2016)... , ... May 02, 2016 , ... For many artists, ... artist Curt Walter has developed it into a science. , Using the new, ... achieve subtly differentiated shades that add depth and meaning to his works. What’s more, ...
Breaking Medicine News(10 mins):